

**2008 Schedule**

**NORTH AMERICAN CONGRESS OF CLINICAL  
TOXICOLOGY**

**ANNUAL MEETING**

**September 11-16, 2008**



**Program Outline**

**Program Committee**

**Education Committee**

**Abstract Review Committee**

# PRELIMINARY PROGRAM OUTLINE

*\*\* Subject to Change\*\**

**Thursday, September 11, 2008**

7:00 am – 5:00 pm Speaker Ready Room  
VIP Room (Concourse level)

**7:00 am – 8:00 am** **ACMT Pre-Meeting Symposium: Registration/Information**  
**Lower Concourse** **The Changing Face of the Toxicology Patient**

**7:00 am – 8:00 am** **Continental Breakfast**  
**Grand Ballroom Foyer**

**8:00 am – 4:00 pm** **ACMT Pre-Meeting Symposium: The Changing Face of the**  
**Grand Ballroom** **Toxicology Patient**  
**Moderators: Suzanne White, MD**  
**Dave Barry, MD**

***Bariatric Toxicology: A Unique, Emerging Population***

Howard A. Greller, MD, FACMT

Assistant Professor, NYU School of Medicine, New York, NY

***Coping with Teen Angst in our Complex iWorld?: The Toxicology of Pediatric Psychiatry***

Mark B Mycyk, MD

Director of Clinical Toxicology, Northwestern University School of Medicine, Chicago, IL

***Diabetes Toxicology at the Dawn of the 21<sup>st</sup> Century***

Jeffrey R Suchard, MD, FACMT, FACEP

Associate Professor of Clinical Emergency Medicine, Director of Medical Toxicology, UC Irvine Medical Center, Orange, CA

***Boomer Users: The Toxicology of Aging and Drug Abuse***

Suzanne White, MD, FACMT, FACEP

Dayanandan Professor and Chair, Department of Emergency Medicine, Wayne State University, Detroit, MI

***HIV & Poisoning: The Evolution of a Toxic Pandemic***

Sean M Bryant, MD

Assistant Professor of Emergency Medicine, Cook County Hospital, Chicago, IL

***The Pregnant and Breastfeeding Patient as a Toxicological Orphan***

Gideon Koren, MD, FRCPC, FACMT

Director, the Motherisk Program, The Hospital for Sick Children, Professor of Pediatrics, Pharmacology, Pharmacy, and Medical Genetics, The University of Toronto, Toronto, Canada

***Toxicological Emergencies in Oncology Patients***

Rama B. Rao, MD

Bellevue Hospital Center, New York, NY

## Thursday, September 11, continued

### *Over-the-Hill and Into the Medicine Cabinet: A Look at Geriatric Toxicology*

David N. Juurlink, BPharm, MD, PhD, FRCPC, FACMT, FAACT, Head, Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre, Scientist, Institute for Clinical Evaluative Sciences, Toronto, Canada

### *When the Beans Are Already Bad – The Impact of the Evolving Renal Failure Population on Toxic Thought.*

Kurt C. Kleinschmidt, MD, FACEP, FACMT  
Associate Professor of Surgery, Division of Emergency Medicine, Chief of the Section of Medical Toxicology, UT Southwestern Medical School, Dallas, TX

#### **The participant at the end of this session should be able to:**

1. Describe how morbid obesity alters pharmacokinetics and toxicokinetics.
2. Discuss the adjustments necessary for antidotal therapy in the morbidly obese.
3. Describe how various therapies for morbid obesity can alter a patient's susceptibility to toxins.
4. Describe the major physiologic changes that distinguish pediatric from adult patients.
5. Discuss recent trends in the treatment of pediatric psychiatric illnesses.
6. Discuss the pharmacology and toxicology of psychiatric medicines used to treat pediatric patients.
7. Describe changes in diabetic patients as they relate to medical toxicology.
8. Discuss recent trends in the toxicologic experience with diabetes medications.
9. Discuss the pharmacology and toxicology of newer antidiabetic drugs and drug classes.
10. Identify emerging patterns of substance abuse relative to the aging population.
11. Discuss the impact of substance abuse on the aging brain.
12. Recognize pitfalls in the management of older patients who abuse substances.
13. Discuss the pharmacology and toxicology of HIV and anti-retroviral therapy.
14. Describe popular herbal medicinal and alternative therapies used in the treatment of HIV.
15. Identify major complications and side-effects of HIV therapies.
16. Discuss treating the mother and protecting the unborn.
17. Discuss principles of maternal-fetal toxicology.
18. Describe principles of risk-benefit analysis of drug therapy in pregnancy.
19. Identify toxicological emergencies in the oncology patient.
20. Describe the risks of chemotherapeutic extravasations and current treatment options.
21. List newer interventions and antidotes for specific chemotherapeutic overdoses.
22. Describe the main physiologic changes associated with aging.
23. Discuss some common comorbidities in the elderly, and their relevance to toxicology.
24. Describe the pharmacology of selected medications commonly used by the elderly.
25. Describe toxicities that have occurred as complications of dialysis.
26. Compare key considerations about the use of medications in renal failure patients that have had or not had a transplant.
27. Discuss the medical implications of the changing renal failure population

11:45 am – 1:00 pm ACMT Business Meeting  
Sheraton Hall A  
(Lower Concourse)

## **Thursday, September 11, continued**

12:00 pm – 6:00 pm ABAT Certification Examination  
Simcoe (2<sup>nd</sup> Floor)

**3:00 pm – 5:00 pm** **AACT Pre-Meeting Symposium: Registration/Information**  
**Lower Concourse** **Transportation Toxicology: Planes, Trains and Automobiles – And Boats, Too**

4:00 pm – 11:00 pm AACT Board Meeting  
Dufferin (2<sup>nd</sup> Floor)

**4:00 pm – 6:00 pm** **ACMT Medical Toxicology 10<sup>th</sup> Annual CPC Competition**  
**Grand Ballroom** **Moderator: Jeffrey Suchard, MD, FACMT, FACEP**

**Presenters:**  
**Kevin Kent**  
**Nima Majlesi**  
**Shawn Varney**

**Faculty Dissucants:**  
**Steve Bird**  
**Gar Chan**  
**Jason Hoppe**

**The participant at the end of this session should be able to:**

1. Formulate an approach to the diagnosis of complex poisoning cases based on limited data
2. Describe the management of several unique poisonings
3. Identify potential pitfalls in the diagnostic approach to poisoned patients

6:00 pm – 7:30 pm ACMT Fellow's Reception  
Waterfall Garden (2<sup>nd</sup> Floor)

7:00 pm – 9:00 pm AAPCC Council of Medical Directors  
Sheraton Hall E (Lower Concourse)

---

---

## **Friday, September 12, 2008**

7:00 am – 6:00 pm Speaker Ready Room  
VIP Room (Concourse)

**7:00 am – 8:00 am** **AACT Pre-Meeting Symposium: Registration/Information**  
**Lower Concourse** **Transportation Toxicology: Planes, Trains and Automobiles – And Boats, Too**

**Friday, September 12, 2008, continued**

**7:00 am – 8:00 am Continental Breakfast  
Grand Ballroom Foyer**

8:00 am – 1:00 pm ABAT Certification Examination  
Simcoe (2<sup>nd</sup> Floor)

9:0 am – 3:00 pm Public Education Track  
Sheraton Hall A (Lower Concourse)

**7:50 am – 5:40 pm AACT Pre-Meeting Symposium: Transportation Toxicology: Planes,  
Grand Ballroom Trains, Automobiles – And Boats, Too  
Moderator: Robert B Palmer, PhD, DABAT**

***Approaches to Assessing Drug –Related Driving Impairment***

Barry K Logan, PhD, DABFT

Seattle, WA

***Epidemiology and Risk Assessment of Toxic Hazards in the Motor  
Vehicle Manufacturing Industry***

Franklin Mirer, PhD, CIH

Professor, Hunter College Urban Public Health Program, New York, NY

***Railroad Hazardous Materials Incidents - Response Through  
Mitigation, Rehabilitation and Recovery***

Glenn C Millner, PhD, CIH

Senior Toxicologist, Center for Toxicology and Environmental Health,  
Little Rock, AR

Patrick Brady, CIH, CSP

Assistant Director of Hazardous Materials, BNSF Railway, Fort Worth,  
TX

***Health & Safety Concerns During Major Oil Spills***

Joseph B Loring, LCDR, USCG

Medical College of Ohio, Toledo, OH

***“And They Didn’t File a Flight Plan”: Forensic Toxicology and Pilot  
Impairment in General Aviation***

Robert B. Palmer, PhD, DABAT

Toxicology Associates, PLLC, Assistant Clinical Professor, University of  
Colorado School of Medicine, Denver, CO

***Flying Through the Air with the Slightest “Dis-ease”: Aircraft  
Exposures and an Aging Flying Public***

Eileen M. McNeely, PhD, RNC

Instructor, Harvard School of Public Health, Boston, MA

***Toxicology and the Commercial Space Travel Industry***

Richard J. Hamilton, MD, FAAEM, FACMT

Associate Professor and Chairman, Department of Emergency Medicine,  
Drexel University College of Medicine, Hahnemann University Hospital,  
Philadelphia, PA

## **Friday, September 12, 2008, continued**

### **The participant at the end of this session should be able to:**

1. Describe at least four approaches to assessing likely impact of a drug on driving performance.
2. Discuss the basis of field tests for impairment, including cognitive/psychomotor divided attention tests, observations of driving, and documentation of physiological effects related to drug use.
3. Describe the various specimens available for testing drivers for drug use and the relative advantages and disadvantages of each.
4. List the major production processes in the manufacture of motor vehicles.
5. Describe the most prominent chemical exposures associated with each of the vehicle production processes.
  
6. Discuss the known and suspected health effects associated with these chemical exposures and exposure circumstances.
7. Discuss the issues and techniques surrounding the preparation for and execution of the response to railroad chemical emergencies through the use of a model emergency response framework from the initial stages of the response through mitigation, rehabilitation, and recovery.
8. Describe protection of the HAZMAT team, monitoring and modeling of exposures, triage medical case management communication, available toxicology emergency response guidelines, and considerations for regulatory notification, media relations, and post-incident health assessments.
9. Discuss emerging issues in emergency planning and response affecting chemical emergencies in railroads.
10. Describe health and safety concerns of oil spill responder.
11. Discuss basic PPE and potential remediation techniques.
12. Discuss time's effect on spilled oil, health effects and changing cleanup techniques.
13. Describe the risks of impairment to general aviation pilots due to use, misuse and abuse of drugs and alcohol.
14. Discuss data and limitations associated with interpretation of postmortem forensic toxicology data from general aviation crashes.
15. Describe possible exposures in flight and potential health consequences.
16. Discuss recent study findings by the Airliner Cabin Environment Research (ACER) group about airborne contaminants such as ozone, infectious disease and organophosphates.
17. Describe the technological developments in the commercial space industry.
18. Describe the toxicology of rocket fuels and motors as well composite material construction.
19. Discuss the toxicological issues facing the commercial space industry based on an understanding of the development of the commercial air industry.

8:00 am – 5:00 pm ABAT Board Meeting  
Wentworth (2<sup>nd</sup> Floor)

11:00 am – 5:00 pm AAPCC Accreditation Committee  
Kenora (2<sup>nd</sup> Floor)

12:30 pm – 7:30 pm ACMT Board of Directors  
Huron (2<sup>nd</sup> Floor)

**1:00 pm – 5:00 pm NACCT Main Congress: Registration/Information**  
**Lower Concourse**

3:15 pm – 4:15 pm PEC New Educator Orientation  
Kent (2<sup>nd</sup> Floor)

4:15 pm – 5:30 pm PEC Meet and Greet  
Sheraton Hall B (Lower Concourse)

5:00 pm – 6:00 pm AAPCC Staff Development  
Kent (2<sup>nd</sup> Floor)

## **Friday, September 12, 2008, continued**

5:00 pm – 8:00 pm Clinical Toxicology Strategic Planning Meeting  
Dufferin (2<sup>nd</sup> Floor)

6:00 pm – 7:00 pm AAPCC Benchmarking/QA/Audit  
Sheraton Hall A (Lower Concourse)

6:00 pm – 7:30 pm PEC Swap-N-Share  
Sheraton Hall B (Lower Concourse)

7:00 pm – 8:00 pm AAPCC Mid-Year Planning Meeting  
Kent (Lower Concourse)

7:00 pm – 8:00 pm AAPCC Computerization Meeting  
Kenora (Lower Concourse)

7:00 pm – 10:00 pm AAPCC SPI Committee Meeting  
Simcoe (2<sup>nd</sup> Floor)

7:30 pm – 8:00 pm PEC AAPCC Update  
Sheraton Hall A (Lower Concourse)

8:00 pm – 9:30 pm PEC Committee Meeting – Open Meeting and Reports  
Sheraton Hall A (Lower Concourse)

---

---

## **Saturday, September 13, 2008**

7:30 am – 5:00 pm Speaker Ready Room  
VIP Room (Concourse Level)

**7:00 am – 5:00 pm Registration/Information**  
**Lower Concourse**

7:00 am – 8:00 am ACMT P&T/Patient Safety  
Huron (2<sup>nd</sup> Floor)

**7:00 am – 8:30 am Continental Breakfast**  
**Lower Concourse**

8:00 am – 9:30 am PEC Joint Steering Committee  
Dufferin (2<sup>nd</sup> Floor)

**Saturday, September 13, 2008, continued**

**8:30 am – 9:30 am NACCT Keynote Presentation**

**Grand Ballroom**

**Dr. Gordon Guyatt**

*(Sponsored by Protherics PLC)*

**Opening Remarks**

**G. Randall Bond, MD**

*President, American Academy of Clinical Toxicology*

**Stuart Heard, PharmD**

*President, American Association of Poison Control Systems*

9:00 am – 10:00 am ACMT ATSDR Network  
Huron (2<sup>nd</sup> Floor)

9:00 am – 5:00 pm Toxicall Training  
Kent (2<sup>nd</sup> Floor)

9:00 am – 10:00 am ACMT JMT Editors  
Kenora (2<sup>nd</sup> Floor)

9:15 am – 5:30 pm PEC Education Track  
Sheraton Hall A (Lower Concourse)

**9:30 am – 10:00 am Break**  
**Lower Concourse**

**10:00 am – 12:00 pm ACMT Scientific Symposium: Stem Cells in Toxicology**

**Grand Ballroom**

**Moderator: Lydia Baltarowich, MD**

***Human Embryonic Stem Cells: Discovering Novel Approaches to Predictive Toxicology***

Gabriela Gebrin Cezar, DVM, PhD

Assistant Professor, University of Wisconsin-Madison, Madison, WI

***Issues and Controversies Related to Human Embryonic and Adult Stem Cells Use in Drug Discovery and Safety Assessment***

James E. Trosko, PhD

Professor of Pediatrics/Human Development, Michigan State University, Lansing, MI

The participant at the end of this session should be able to:

1. Provide an overview of embryonic stem cell technology use in toxicology.
2. Discuss metabolomics and its correlation with scientific and clinical outcomes.
3. Recognize the association of metabolomics to human embryonic stem cell technology as a means to identify human candidate biomarkers of toxic response.
4. Recognize the ethical, scientific, and technological challenges in utilizing stem cells for drug discovery and safety assessment.
5. Distinguish between embryonic and adult stem cell applications in toxicology
6. Review the status of current guidelines on the use of human embryonic stem cells for toxicology testing.

**10:00am – 12:00pm AAPCC SPI Symposium I: Pediatric Drug Safety**

**Osgood Ballroom**

**Moderators: Kathryn H. Meier, PharmD, DABAT, CSPI**

**Lower Concourse**

**Cindy M. Siptak, RN, MSN, CSPI**

**Carol DesLauriers, PharmD, CSPI**

**Saturday, September 13, 2008, continued**

***Discovery, Development and Surveillance - Making Drugs Safe for Children.***

Michael Shannon, MD, MPH

Professor of Pediatrics, Harvard Medical School, Children's Hospital  
Boston, Boston, MA

***The Evolution of Monitoring and Regulation of Drug Safety in Children***

William Banner Jr, MD, PhD

Clinical Professor, Oklahoma University, The Children's Hospital at St  
Francis, Tulsa, OK

The participant at the end of this session should be able to:

1. Describe how pediatric drug safety is currently evaluated and how it may be changing.
2. Identify methods for post-marketing pediatric drug surveillance and understand how SPIs may play a part in this.
3. List case examples of drugs that were determined as safe but proved harmful or dangerous.
4. Compare and contrast "approved" and "off label" use of drugs in the pediatric population.

12:00 pm – 1:30 pm Lunch Break

12:00 pm – 1:30 pm AACT Strategic Planning Meeting  
Huron (2<sup>nd</sup> Floor)

12:00 pm – 1:30 pm Middle Eastern Tox Group Committee Meeting  
Kenora (2<sup>nd</sup> Floor)

12:30 pm – 1:30 pm ACMT Medical Toxicology Institute  
Dufferin (2<sup>nd</sup> Floor)

12:30 pm – 1:30 pm AAPCC Managing Directors  
Sheraton Hall B (Lower Concourse)

**1:30 pm – 3:30 pm EAPCCT Symposium: Antidotes for Poisoning: An Update on the Evidence**  
**Grand Ballroom East**

**Moderators: Hugo Kupferschmidt, MD  
Martin Caravati, MD**

***Use of oral activated charcoal in poisoning. How should the latest evidence affect clinical practice?***

Michael Eddleston, PhD, MRCP

Scottish Poisons Information Bureau and University of Edinburgh,  
Edinburgh, UK

***Recent advances in the management of calcium channel blocker poisoning***

Bruno Mégarbane, MD, PhD

Professor, University Paris 7, Lariboisière Hospital, Paris, France

***Progress in antidote therapy for pesticide and herbicide poisoning***

Martin F. Wilks, MD, PhD

Syngenta Crop Protection AG, Basel, Switzerland

## **Saturday, September 13, 2008, continued**

The participant at the end of this session should be able to:

1. Discuss recent evidence on the benefit and risks of activated
2. Describe the proposed mechanisms of action of multiple dose activated charcoal
3. Discuss the indications and limits of calcium salts, glucose insulin, glucagon, aminopyridines, terlipressin, and vasopressin in the management of calcium channel blocker poisoning
4. Identify refractory shock requiring extracorporeal life support
5. Discuss the role of antidotes in the therapy of the most common forms of pesticide poisoning
6. Discuss the latest evidence with regard to the benefits of oxime therapy in organophosphate poisoning, and the development of new therapies for paraquat poisoning

**2:30 pm – 3:30 pm    AACT Year In Toxicology I: Mercury in Seafood**  
**Grand Ballroom    Moderator: Jeffrey Brent, MD, PhD**  
**Centre**

Gary Myers, MD  
Professor of Neurology, Pediatrics and Environmental Medicine,  
University of Rochester Medical Center, Rochester, NY

The participant at the end of this session should be able to:

1. Describe the data on the amount of mercury found in seafood
2. Assess the significance of this data to human health

**2:00 pm – 5:00 pm    Exhibit Set-Up/Poster Session I**  
**Sheraton Hall EF /   Abstracts: # 18-111**  
**Grand Ballroom**

**2:00 pm – 5:00 pm    Public Educator Displays Set – Up**  
**Sheraton Hall A Foyer**  
**Lower Concourse**

**3:30 pm – 4:00 pm    Refreshment Break**  
**Lower Concourse**

**4:00 pm – 6:00pm    IPCS/APAMT Symposium: International Health Regulations (2005)**  
**Grand Ballroom    and Field Investigation of Disease Outbreaks of Toxicological and**  
**Centre                Unknown Etiology**

**Moderators:    Tim Meredith, MD**

**Andrew Dawson, MD**

*International Health Regulations (2005)-Scope and Application*

Joanna Tempowski

Scientist, International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland

*Outbreak of Neurological Illness of Unknown Etiology in Cacuaco Municipality, Angola*

Thomas Zilker, MD

Professor and Director of Clinical Toxicology, Technical University Munich (TUM), Munich, Germany

*Mass Paralysis as a Consequence of Bamboo Shoot Ingestion: A Case Study in Thailand*

Winai Winanukul, MD

Associate Professor, Mahidol University, Bangkok, Thailand

**Saturday, September 13, 2008, continued**

***International Migration and Hepatotoxicity in Bangladesh***

Md. Abul Faiz, FCPS, FRCP, PhD

Professor and Director General of Health Services, Ministry of Health & Family Welfare, Govt. of the Peoples Republic of Bangladesh, Dhaka, Bangladesh

The participant at the end of this session should be able to:

1. Describe the scope of the International Health Regulations (2005)
2. List two criteria for notifying WHO of a disease outbreak
3. Discuss the difficulties of diagnosis in the Angola outbreak
4. List three clinical features of sub-acute sodium bromide poisoning
5. Describe the differential diagnosis of paralysis outbreaks in Asia
6. Discuss coordination of national and international field responses
7. Describe the differential diagnosis of hepatic failure outbreaks in Asia
8. Discuss the approach to diagnosis in resource-restricted areas

**4:00 pm – 5:00 pm    Platform Session #1: Poison Centers**

**Grand Ballroom    Abstract's # 1-4**

**East**

**Moderator: Stuart Heard, PharmD**

**Karen Simone, PharmD**

1. Poison Centers and Medical Cost Avoidance: Revisiting the Concept \$7 Saved for Every \$1 Spent. Hilton J, Wahl M.

2. Health Care Costs Associated with the Management of Childhood Poisonings: Impact of the Poison Control Center. Kim R, Lee K, Hiatt P.

3. Analysis of Data from a Novel Drug Identification Service. Doyon S, Anderson BA, Welsh CJ, Klein-Schwartz W, Hayes BD.

4. Hazardous Materials Incidents: Should Poison Centers Be More Involved?. Sutter ME, Hon S, Chang A, Schwartz M, Algren DA, Schier J, Lando J.

The participant at the end of this session should be able to:

1. Discuss the concept of poison centers and medical cost avoidance.
2. Describe health care costs associated with management of childhood poisonings.
3. Discuss data derived from a novel drug identification service.
4. Describe the role of poison centers in hazardous materials incidents.

**4:00 pm – 6:00 pm    NLM Symposium: Online Resources and Tools in Support of Clinical**

**Osgood Ballroom    Toxicology**

**Lower Concourse**

**Moderator: Philip Wexler**

***Emerging Online Tools in Support of Toxicology Information***

Asish Mohapatra, MSc, MPhil (pre-doctoral), EMC. Risk An. Cert.  
(Harvard)

Risk Assessment Consultant, Calgary Health Region, Calgary, Canada

***Cornell Poisonous Plants Database***

Dan Brown, PhD

Cornell University, Ithaca, NY

**Saturday, September 13, 2008, continued**

***Information Tools from the Canadian Center of Occupational Safety and Health***

P.K. Abeyunga, MSc, PhD

Vice-President and Director General, Canadian Centre for Occupational Health and Safety (CCOHS), Hamilton, Canada

***The INTOX Data Management System***

Joanna Tempowski

Scientist, International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland

***Management and Utilization of Data on Toxic Exposures in Chili using IPCS INTOX***

Juan Carlos Rios, PhD

Assistant Professor, Poison Center Catholic University (CITUC), Hospital Clinico de la Universidad Católica, Santiago, Chile

***IPCS INTOX DMS as a flexible tool for multi-centre use: The Experience from Brazil (Presentation not audio taped)***

Ligia Fruchtengarten, MD, MSc

Poison Control Centre of São Paulo, São Paulo, Brazil

The participant at the end of this session should be able to:

1. Describe the scope of recent online technologies in support of toxicology
2. Identify and differentiate various specific online tools and their uses.
3. Discuss how to conduct basic online searches for poisonous plants.
4. Determine which animal species are most often affected by a given plant.
5. Describe the wide range of internationally peer reviewed information and other services provided by the Canadian Centre for Occupational Health and Safety for the prevention, control and management of toxic exposures
6. Identify the optimum use of the toxicology related information and services available from CCOHS to fulfill their specific needs.
7. Describe the INTOX data management system.
8. Discuss how the INTOX system might be used by poisons centres in the developing world.
9. Discuss how the INTOX system may benefit well-established and busy poison centres.
10. Discuss the elements of the IPCS INTOX database
11. Describe data entry into the INTOX database
12. List methods to retrieve data from the database
13. Discuss Data Management System requirements for the collection, analysis and reporting of poisoning cases
14. List Harmonized terminology for registering poisoning cases
15. Describe the IPCS INTOX Data Management System

4:00 pm – 6:00 pm PCC Collaborative Communication Training Program  
Kenora (2<sup>nd</sup> Floor)

5:00 pm – 6:00 pm ACMT International Medical Toxicology Interest Group  
Dufferin (2<sup>nd</sup> Floor)

**Saturday, September 13, 2008, continued**

**5:00 pm – 6:00pm Platform Session #2: Toxicity & Laboratory**

**Grand Ballroom Abstracts # 5-9**

**East**

**Moderator: Jou Feng Deng, MD**

**Christopher Holstege, MD**

5. Quantitative Bedside Screening Test for Methaemoglobin. Shihana HSF, Dissanayake DM, Dawson A.

6. The Effect of Acetadote on Prothrombin Time in Plasma Samples from Healthy Subjects. Pizon AF, Jang DH, Wang HE.

7. Fomepizole Inhibit Diethylene Glycol Toxicity and Metabolism in Rats. McMartin KE, Besenhofer LM, Cain M, Latimer B.

8. Escitalopram Causes Fewer Seizures in Human Overdose Than Citalopram. Yilmaz Z, Rauber C, Sauer O, Stedtler U, Prasa D, Seidel C, Hackl E, Hoffmann P, Gerber G, Bauer K, Kupferschmidt H, Kullak G, Wilks M.

9. Probable Benefit of Hyperinsulinemia-Euglycemia and Hyperventilation Oxygenation on Aluminium Phosphide Poisoning. Hassanian-Moghaddam H.

The participant at the end of this session should be able to:

1. Describe a quantitative bedside screening test for methaemoglobin.
2. Discuss the effect of Acetadote on prothrombin time in plasma samples from healthy subjects.
3. Describe the effects of fomepizole on diethylene glycol toxicity and metabolism in rats.
4. Discuss the data concerning seizure incidence following escitalopram overdose.
5. Discuss the evidence concerning benefits of hyperinsulinemia-euglycemia and hyperventilation oxygenation in aluminum phosphide poisoning.

**6:00 pm – 7:00 pm Opening Reception**

**Civic Ballroom (2<sup>nd</sup> Floor)**

**7:00 pm – 9:00 pm Toxicology History Society**

**Grand Ballroom Moderator: John H. Trestrail III, RPh, FAACT, DABAT**

**History of Toxicology, Part I**

**Cyrus Rangan & Rais Vohra**

**The Skull and Crossbones: A Symbolic History of Death, Piracy and Poison**

**Timothy Erickson**

**Death in the ICU: Charles Cullen, How did he get away with it for so long**  
**Steven Marcus**

**When Your Wish Upon A Poison: Toxic Moments from the Wonderful World of Disney**

**Melissa Vandenberg & Sharon Jenson**

**Sunday, September 14, 2008**

7:00 am – 5:00 pm Speaker Ready Room  
VIP Room (Concourse Level)

**7:00 am – 5:00 pm Registration/Information**  
**Lower Concourse**

**7:00 am – 8:30am Continental Breakfast**  
**Lower Concourse**

7:00 am – 8:00 am AACT Envenomations SIG  
Simcoe (2<sup>nd</sup> Floor)

7:00 am – 8:30 am AACT Multicenter Research Grant Update  
Sheraton Hall B  
Lower Concourse

8:00 am – 10:00 am ACMT Education Committee  
Dufferin (2<sup>nd</sup> Floor)

8:00 am – 6:00 pm PEC Education Track  
Sheraton Hall A (Lower Concourse)

8:00 am – 9:00 am Clinical Toxicology Strategic Planning  
Kenora (2<sup>nd</sup> Floor)

**8:00 am – 8:15 am Presentation of International Travel Scholarship Awards:**  
**Grand Ballroom Moderator: Daniel J. Cobaugh, PharmD, FAACT**

5. Quantitative Bedside Screening Test for Methaemoglobin. Shihana HSF, Dissanayake DM, Dawson A.

9. Probable Benefit of Hyperinsulinemia-Euglycemia and Hyperventilation Oxygenation on Aluminium Phosphide Poisoning. Hassanian-Moghaddam H.

160. Management of Paediatric Poisoning at a Referral Hospital in Zimbabwe. Gadaga LL, Mufukari N, Tagwireyi D.

**8:15 am – 10:15 am AACT Symposium: Bias and Thought Control: They're Not Just For**  
**Grand Ballroom Toxicologists Anymore**  
**Moderators: David Juurlink, MD, PhD, BPharm, FRCPC, FACMT,**  
**FAACT**  
**Marco Sivilotti, MD**

***Medical Journals and Thought Control***

Matthew B. Stanbrook, MD, PhD

Assistant Professor, Department of Medicine, University of Toronto, Staff  
Physician, Division of Respiriology, University Health Network, Toronto,  
Canada





**Sunday, September 14, 2008, continued**

**12:00 pm – 1:30 pm Lunch on Own**

12:00 pm – 1:30 pm AAPCC Committee Chair Lunch  
Simcoe (2<sup>nd</sup> Floor)

12:30 pm – 1:30 pm ACMT Foundation  
Kenora (2<sup>nd</sup> Floor)

12:30 – 1:30 pm ACMT Website Interest Group  
Huron (2<sup>nd</sup> Floor)

1:30 pm – 3:30 pm ACMT Fellowship Directors  
Kenora (2<sup>nd</sup> Floor)

**1:30 pm – 4:30 pm AACT Herbal Special Interest Group Poster Session / Meeting**  
**Sheraton Hall B Moderator: Alan Woolf, MD, MPH**  
**(Lower Concourse)**

41. Kratom: A Case of a Legal High Roche KM, Hart K, Sangalli B, Lefberg J, Bayer M. CT Poison Control Center, Farmington, CT, USA

94. Severe Health Impairment of a 6-Week-Old Infant Related to the Ingestion of Boiled Poppy Seeds  
Hahn A, Michalak H, Begemann K, Meyer H, Burger R, Luch A. Federal Institute for Risk Assessment (BfR), Berlin, Germany.

42. Selenosis from Nutritional Supplement Formulation Error Sutter ME,<sup>1,2,3</sup> Thomas JD,<sup>1,2,3</sup> Caldwell KL,<sup>3</sup> Makhmudov A,<sup>3</sup> Morgan BW.<sup>1,2</sup> <sup>1</sup>Emory University; <sup>2</sup>Georgia Poison Center; <sup>3</sup>CDC, USA.

104. Muscular Spasm with Therapeutic Doses of Cang Er Zi West PL, McKeown NJ, Hendrickson RG. Oregon Poison Center, Portland, OR, USA.

257. Psychosis Temporally Related to Supratherapeutic Manganese Supplementation Leikin JB,<sup>1</sup> Mottram AR.<sup>2</sup> <sup>1</sup>Evanston Northwestern Healthcare OMEGA, Glenview, IL; <sup>2</sup>Toxicology/Emergency Medicine, Cook County-Stroger Hospital, Chicago, IL, USA

153. A Recent Outbreak of Honey Poisoning Linked to the Tutu Plant (*Coriaria arborea*) Beasley DM. National Poisons Centre, University of Otago, Dunedin, New Zealand.

171. Adverse Effects Associated with Arginine Alpha-Ketoglutarate Containing Supplements  
Prosser JM,<sup>1</sup> Majlesi N,<sup>2</sup> Nelson LS,<sup>1</sup> Olsen D.<sup>1,3</sup> <sup>1</sup>New York City Poison Center, NY, NY, USA; <sup>2</sup>North Shore University Hospital, Manhassat, NY, USA; <sup>3</sup>St. Barnabas Hospital, NY, NY, USA

196. Adverse Outcome with Bloodroot Salve Treatment Zaret LS, Zusthi D, John J Cienki. Jackson Memorial Hospital/Miller School of Medicine of the University of Miami, Miami, FL, USA

## **Sunday, September 14, 2008, continued**

The participant at the end of this session should be able to:

1. Discuss intoxication with Kratom.
2. Describe severe health impairment related to ingestion of boiled poppy seeds by an infant
3. Describe a case of selenosis from nutritional supplement formulation error
4. Discuss a case of muscular spasms related to Cang Er Zi use
5. Describe a case of psychosis temporally related to supratherapeutic manganese supplementation
6. Discuss a recent outbreak of honey poisoning linked to the Tutu plant
7. List adverse effects associated with Arginine Alpha-Ketoglutarate containing supplements
8. Describe an adverse outcome associated with Bloodroot Salve treatment

**1:30 pm – 3:30 pm**    **AACT Occupational/Environmental Symposium I: Environmental Forensics and Hormesis**  
**Grand Ballroom**    **Moderator: John A. Curtis, MD**  
**Centre**

### ***Environmental Forensics***

Allen Uhler, PhD (**Presentation not audio taped**)

NewFields Environmental Forensics Practice

Rockland, MA

### ***Hormesis: Its Significance to Toxicology, Risk Assessment and Medicine***

Edward Calabrese, PhD.

Professor of Toxicology, University of Massachusetts, Amherst, MA

The participant at the end of this session should be able to:

1. Describe the various technologies used to characterize contaminated sites
2. Explain how proper site characterization impacts risk assessment
3. Acquire understanding of the history of the dose response concept and the methods by which hormesis is evaluated
4. Develop an understanding of how the threshold and hormesis models can be assessed for their capacity to predict responses below the toxicological/pharmacological threshold
5. Develop an understanding of how hormesis is likely to affect the fields of toxicology, risk assessment and clinical medicine

**1:30 pm – 3:30 pm**    **AAPCC SPI Symposium II: Unique and Practical Approaches Among Different PCCs**  
**Grand Ballroom**    **Moderator: Lynn F. Durback-Morris, BSN, MBA, CSPI, DABAT**  
**East**

Donna Smyth, RN, CSPI

Ontario Poison Centre and Hospital For Sick Children, Toronto, Canada

Carol DesLauriers, PharmD, CSPI

Illinois Poison Center, Chicago, IL

Twyla Kimball RN, BSN, CSPI

Tampa General Hospital, Tampa, FL

The participant at the end of this session should be able to:

1. Describe differences / similarities with respect to drug identification policy within / between poison centers.
2. Analyze the degree of variability in poison center specialists function.
3. Demonstrate how poison centers identify population - specific needs and address them.
4. Describe decontamination techniques employed by specialists among different poison centers.
5. Define the circumstances under which recommendations for a specific therapeutic intervention may be altered.
6. Evaluate how the various methodologies discussed may be applied to other poison centers.

**Sunday, September 14, 2008, continued**

**3:30 pm – 4:00 pm Break**  
**Grand Foyer**

3:30 pm – 5:30 pm AAPCC Data Collection Committee  
Sheraton Hall C (Lower Concourse)

**3:30 pm – 4:30 pm AACT Year In Toxicology II : Can Drugs Cause Suicide? A Critical Analysis of the Evidence**  
**Grand Ballroom Centre Moderator:**

David N. Juurlink, BPharm, MD, PhD, FRCPC, FACMT, FAACT, Head,  
Division of Clinical Pharmacology and Toxicology, Sunnybrook Health  
Sciences Centre, Scientist, Institute for Clinical Evaluative Sciences, Toronto,  
Canada

The participant at the end of this session should be able to:

1. Discuss recent alerts linking various drugs with suicide
2. Describe what different types of evidence can (and cannot) tell us about adverse drug events

**4:00 pm – 6:00 pm AAPCC SPI Roundtable**  
**Grand Ballroom East Moderator: Twyla Kimball, RN,CSPI**

***Can a Phenobarbital Overdose Treated with Multi-dose AC with Sorbitol Result in an Osmolar Gap?***

Ann P. Slattery, RN, RPh, DrPH, CSPI, DABAT  
Supervisor, Regional Poison Control Center, Children's Hospital, Birmingham,  
AL

***Methotrexate***

Deborah A. Anguish RN, CSPI  
Upstate New York Poison Center, Syracuse, NY

***Getting Your Hand Caught in the Pharmaceutical Candy Jar!***

Jan Scaglione, MT, PharmD, DABAT  
Assistant Professor of Pharmacy Practice, Senior Drug and Poison Information  
Specialist, Cincinnati Childrens Hospital Medical Center

***Is It Just Diphenhydramine?***

Mark L. Winter, PhD, DABAT  
Assistant Professor in Pharmacology and Toxicology, The University of Texas  
Medical Branch, Galveston, TX

## **Sunday, September 14, 2008, continued**

### **Discussants**

Matthew D. Sztajnkrycer, MD, PhD, Associate Professor of Emergency Medicine, Mayo Clinic, Rochester, MN

Susan C. Smolinske, PharmD, BCPS, DABAT, Children's Hospital of Michigan Regional Poison Control Center, Detroit, MI

Rutherford Rose, FAACT, PharmD, DABT, Professor of Emergency Medicine, VCU Medical Center, Director, Virginia Poison Center, Richmond, VA

Thomas Arnold, MD, Associate Professor and Chairman, Department of Emergency Medicine, LSU-Shreveport, Shreveport, LA

The participant at the end of this session should be able to:

1. Identify signs and symptoms of phenobarbital toxicity.
2. Differentiate causes of osmolar gaps.
3. Recognize signs and symptoms of methotrexate toxicity.
4. Discuss the indications for leucovorin.
5. Explain how to prioritize clinical toxicity concerns when challenged with a suspected polydrug ingestion.
6. Discuss the rationale in the treatment of a potential polypharmacy exposure.
7. Describe the anticholinergic toxidrome.
8. Summarize treatment recommendations for an diphenhydramine poisoning.

**4:30 pm – 6:00 pm**    **AACT Acute and Intensive Care Symposium: Toxicology Dilemmas & Controversies - Is There Evidence for What We Do?**  
**Grand Ballroom**       **Moderators: Anthony J Scalzo, MD, FAACT, FACMT**  
**Centre**                    **Sean Bryant, MD, FACEP**

### ***Did His Neurons Crash from a Fuel Stabilizer or was it Due to a Lead Foot?***

Brandon K. Wills, DO, MS

Clinical Assistant Professor, Madigan Army Medical Center

Associate Medical Director, Washington Poison Center, Seattle, WA

### ***The MALady of Metformin Overdose***

Anna Arroyo, MD

Toxicology Fellow

Methodist Hospital, Indianapolis, IN

### ***Asystole from Fosphenytoin Infusion: Diluents not Included***

Sam Jackson, MD, MBA

Toxicology Fellow

Banner Good Samaritan Medical Center, Phoenix, AZ

### **Discussants:**

Milton Tenenbein, MD, FAACT, FACMT, FAAP, FACEP, Professor and Director of Emergency Services, Children's Hospital, Winnipeg, Canada

Donna Seger, MD, FAACT, FACEP, ABMT, Associate Professor of Medicine and Emergency Medicine, Medical Director, TN Poison Center, Vanderbilt University Medical Center, Nashville, TN

## **Sunday, September 14, 2008, continued**

### **Discussants, continued**

Robert S. Hoffman, MD, FACMT, FACEP, FAACT, Associate Professor, New York University School of Medicine, New York, NY

Michael Shannon, MD, MPH, Professor of Pediatrics, Harvard Medical School, Children's Hospital Boston, Boston, MA

The participant at the end of this session should be able to:

1. Discuss the neurotoxicity associated with tetraethyl lead (TEL) compounds.
2. Discuss the management of TEL toxicity including sedation, airway support and controversies surrounding chelation.
3. Discuss the clinical presentation and toxic metabolic effects of meformin overdose in a 49 year old woman.
4. Discuss the intensive care management of a critically ill patient with meformin toxicity including the risk/benefit and evidence base for applying hemodialysis or CVVH.
5. Discuss the toxicity of a large intravenous fosphenytoin infusion.
6. Suggest possible management options including advanced life support and potential benefit of extracorporeal removal.

### **3:00 pm – 4:00 pm    Poster Session I Tear Down**

Sheraton Hall EF

### **4:00 pm – 5:00 pm    Poster Session II Set – Up**

Sheraton EF

**Abstracts: # 116-207**

4:00 pm – 5:00 pm    ACMT Publication Committee

Dufferin (2<sup>nd</sup> Floor)

5:30 pm – 10:30pm    AAPCC Board Meeting Part I

Simcoe (2<sup>nd</sup> Floor)

6:00 pm – 8:00 pm    AACT Fellows' Reception

Waterfall Garden (2<sup>nd</sup> Floor)

---

---

**Monday, September 15, 2008**

**7:00 am – 8:30 am Continental Breakfast**  
**Lower Concourse**

7:00 am – 5:00 pm Speaker Ready  
VIP Room (Concourse)

**7:00 am – 5:00 pm Registration/Information**  
**Lower Concourse**

**7:00 am – 8:00 am Midwest Poison Interest Group**  
Wentworth  
(2<sup>nd</sup> Floor)

**8:00 am – 10:00 am ACMT Practice Symposium: New Dimensions in the Practice of**  
**Grand Ballroom Medical Toxicology**  
**Centre Moderator: Jeffrey Brent, MD, PhD**

***The Dedicated Inpatient Toxicology Ward***

J. Ward Donovan, MD, FACMT, FACEP

Medical Director, Pinnacle Health Toxicology Center, Professor Emeritus  
of Emergency Medicine, Pennsylvania State University, Harrisburg  
Hospital, Harrisburg, PA

***The Practice of Outpatient Occupational and Environmental Toxicology***

Scott Phillips, MD, FACMT, FACP

Associate Clinical Professor of Medicine, Occupational Environmental  
Medicine, University of Colorado Health Sciences Center, Lone Tree, CO.

***Lessons Learned from an Inpatient and Outpatient Consulting Practice  
in Medical Toxicology.***

Jerrold Leikin, MD, FACMT, FACP, FACEP, FACCT.

Professor of Emergency Medicine, Evanston Northwestern Healthcare  
OMEGA, Glenview, IL, Senior Attending, Glenbrook Hospital,  
Glenbrook, IL

The participant at the end of this session should be able to:

1. Describe the different models of inpatient medical toxicology practice
2. Discuss some tools to develop an outpatient practice in medical toxicology
3. List the pros and cons of a primary inpatient service versus a consulting service

**8:00 am – 10:00 am CAPCC Symposium: Maternal Fetal Toxicology: Cases from the**  
**Grand Ballroom Motherisk Program**  
**East Moderator: Margaret Thompson, MD**

***Case-based presentation of in utero exposure to drugs and chemicals***

David Chitayat, MD, FCCMG, FRCPC, FABMG, FACMG

Professor, University of Toronto, Hospital for Sick Children, Toronto,  
Canada

**Monday, September 15, 2008, continued**

***Laboratory biomarkers of fetal exposure to drugs of abuse: Case Studies***

Joey Gareri, M.Sc.

Laboratory Director, University of Toronto, Hospital for Sick Children,  
Toronto, Canada

***Drugs in Pregnancy and Lactation: Treating the Mother-Protecting the Unborn***

Gideon Koren, MD, FRCPC, FACMT

Director, the Motherisk Program, The Hospital for Sick Children,  
Professor of Pediatrics, Pharmacology, Pharmacy, and Medical Genetics,  
The University of Toronto, Toronto, Canada

The participant at the end of this session should be able to:

1. List 3 causes of birth defects
2. List 2 determinants of long term fetal drug risk
3. List two examples of the interplay between chemical risk and other fetal
4. List 3 new biomarkers of fetal drug exposure
5. List 3 characteristics of Fetal Alcohol Syndrome
6. List 4 most commonly drugs abused in pregnancy
7. List 3 principles of fetal risk assessment
8. Discuss risk perception by women and healthcare

8:00 am – 9:00 am     AACT Medical/Legal Special Interest Group Meeting  
Simcoe (2<sup>nd</sup> Floor)

8:00 am – 3:00 pm     PEC Education Track  
Sheraton Hall A  
(Lower Concourse)

**9:00 am – 3:00 pm     Exhibits/Poster Session II**  
**Sheraton Hall EF/     Abstracts #116-207**  
**Grand Ballroom Foyer**

9:00 am – 5:00 pm     Public Education Displays  
Sheraton Hall A Foyer

9:00 am – 5:00 pm     Toxicall Training  
Huron (2<sup>nd</sup> Floor)

10:00 am – 11:00 am     AAPCC Veterinary Committee  
Dufferin (2<sup>nd</sup> Floor)

**10:00 am – 11:00 am Authors with Posters/Refreshment Break**  
**Sheraton Hall EF**

10:00 am – 11:00 am     ACMT Practice Committee  
Wentworth (2<sup>nd</sup> Floor)

**Monday, September 15, 2008, continued**

10:00 am – 11:00 am AACT Communication/Technology  
Gingersnap (4<sup>th</sup> Floor)

10:00 am – 11:00 am ACMT Membership Committee  
Cosmopolitan (4<sup>th</sup> Floor)

**11:00 am – 12:00 pm ACMT Ellenhorn Award & Lecture**  
**Grand Ballroom      Moderator: Keith K Burkhardt, MD, FACMT**  
**Centre**

*Regional Poison Treatment Centers: From Delirium Wards to Centers  
of Excellence*

J. Ward Donovan, MD, FACMT, FACEP

Medical Director, PinnacleHealth Toxicology Center, Professor Emeritus  
of Emergency Medicine, Pennsylvania State University,  
Harrisburg Hospital, Harrisburg, PA

The participant at the end of this session should be able to:

1. Discuss the history of the development of regional poison treatment centers
2. Outline the data supporting the need for regional treatment centers to supplement the role of poison control centers (PCC)
3. Review the relationships between PCC and treatment centers, past and future
4. Describe and advocate the need for regional centers to teach, treat, research, and systematize poison treatment

11:30 am – 1:30 pm CAPCC Business Meeting  
Osgood Ballroom  
(Lower Concourse)

11:30 am – 1:00 pm SPI/Steering Committee  
Dufferin (2<sup>nd</sup> Floor)

**12:00 pm – 1:30 pm      Lunch Break**

12:00 pm – 1:30 pm AAPCC Finance Committee  
Gingersnap (4<sup>th</sup> floor)

12:00 pm – 1:30 pm PCC Accreditation Task Force  
Wentworth (2<sup>nd</sup> Floor)

12:00 pm – 1:30 pm Appreciation Luncheon: AACT Special Interest Group Chairs  
Simcoe (2<sup>nd</sup> Floor)

12:00 pm – 1:30 pm ABAT Business Meeting  
Conference Room DE (2<sup>nd</sup> Floor)

**Monday, September 15, 2008, continued**

**12:00 pm – 1:30 pm** **ACMT Fellows-in-Training Luncheon**  
**City Hall**  
**(2<sup>nd</sup> Floor)**

**Moderator: Leslie Dye, MD, FACMT**

*Starting Out: Our First Years at a Tertiary Academic Medical Center as Medical Toxicologists*

James W. Rhee, MD

Assistant Professor of Medicine and Pediatrics, Director of Medical Toxicology, The University of Chicago Medical Center, Chicago, IL.

Trevonne M. Thompson, MD

Assistant Professor of Medicine and Pediatrics, Associate Director of Medical Toxicology, The University of Chicago Medical Center, Chicago, IL.

The participant at the end of this session should be able to:

1. Discuss the groundwork needed to launch a medical toxicology consult service
2. Describe the role of a medical toxicologist at an academic medical center
3. Provide examples of how a highly visible profile helps a medical toxicology consult service become successful
4. Describe how a medical toxicology consult service can help foster relations with other clinical departments
5. List elements required to charge for medical toxicology consultations

**12:30 pm – 1:30 pm** **ACMT Methamphetamine Course**  
**Ice Palace (4<sup>th</sup> Floor)**

**1:30 am – 3:30 pm** **AAPCC Veterinary Toxicology Symposium: Notable Cases from the Pet Food Recall to the Most Common and the Most Deadly**  
**Grand Ballroom East**  
**Moderator: Jan Scaglione, MT, PharmD, DABAT**

*The Pet Food Recall: The Role of the Poison Center and Veterinary Toxicologist*

Steven Hansen, DVM, MS, MBA

ASPCA Animal Poison Control Center/University of Illinois, Urbana, IL

*Animal Poisonings Cases from the Common to the Deadly*

Tina Wismer, DVM, DABVT, DABT

Senior Director of Veterinary Outreach and Education, ASPCA Animal Poison Control Center, Urbana, IL

The participant at the end of this session should be able to:

1. Describe the role of poison center data in emerging animal health emergencies
2. Describe what was learned and how future emergencies will be managed differently
3. Identify the most common toxicities encountered in veterinary medicine.
4. Identify some of the most deadly toxins in veterinary medicine.
5. Describe the mechanism of renal failure in pet food recall



## **Monday, September 15, 2008, continued**

11. List health effects found in children exposed to methamphetamine (acutely and chronically)
12. Describe the use of methamphetamine drug testing in the maternal and pediatric population.

**1:30 pm – 2:30 pm**    **ACMT Fellows-in-Training Roundtable: Opportunities in Government for Medical Toxicologists (This session is not audio taped)**  
**Sheraton Hall C**  
**(Lower Concourse)**

**Moderator: Jeffrey Brent, MD, PhD**

Keith K. Burkhart, MD, FACMT  
Clinical Professor of Emergency Medicine, Penn State College of Medicine, Hershey, PA  
Curtis Snook, MD, FACEP, FACMT  
National Decontamination Team, U.S. EPA, Cincinnati, OH  
Josh G. Schier, MD, FACMT  
Assistant Professor of Emergency Medicine, Section of Toxicology, Grady Health Systems, Centers for Disease Control and Prevention, Atlanta, GA

The participant at the end of this session should be able to:

1. Describe the pros and cons of working as a medical toxicologist for the US government
2. List the governmental agencies that can employ medical toxicologists
3. Discuss the work environment for physicians in the US government

**1:30 pm – 4:30 pm**    **AACT Occupational/Environmental Special Interest Group Poster Session/Meeting**  
**Sheraton Hall B**  
**(Lower Concourse)**    **Moderator: John A. Curtis, MD**

Tetramethylammonium Hydroxide Poisoning: An Emerging and Potentially Life-Threatening Hazard in Semi-Conductor and Photoelectric Industries, Presenting Author: CC Lin

Lack of Conversion to Inorganic Arsenic after Ingestion of a Monosodium Acid Methanearsonate Herbicide, Presenting Author: R J Kleiman

Are We Ready for Prime Time? Prenatal Lead Screening, Presenting Author: D P Calello

Occupational Acute Pulmonary Edema Following Refrigeration Coil Deicing, Presenting Author: N J McKeown

The participant at the end of this session should be able to:

1. Describe trimethylammonium hydroxide poisoning
2. Discuss the metabolism of monosodium acid methanearsonate after ingestion
3. Discuss issues related to the further management of elevated blood levels detected through prenatal lead screening
4. Describe a case of acute pulmonary edema following refrigeration coil deicing

## **Monday, September 15, 2008, continued**

2:00 pm – 4:00 pm Clinical Toxicology Editorial Board Meeting  
Simcoe (2<sup>nd</sup> Level)

2:30 pm – 4:00 pm Medical Toxicology Fellows-In-Training Association  
Sheraton Hall C  
(Lower Concourse)

**3:00 pm – 4:00 pm Poster Session II Removed**  
**Sheraton Hall EF**

3:15 pm – 4:30 pm Open Planning Meeting for 2009 NACCT  
Ice Palace (4<sup>th</sup> Floor)

3:30 pm – 5:00 pm AACT Pediatric Special Interest Group  
Cosmopolitan (4<sup>th</sup> Floor)

**4:00 pm – 5:00 pm Poster Session III Set Up**  
**Sheraton Hall EF Abstracts: #212-305**

**4:00 pm – 5:00 pm Platform Session # 5: Epidemiology**  
**Osgood Ballroom Abstracts: #112-115**  
**(Lower Concourse) Moderators: Maria Mercurio-Zappala, RPh, MS**  
**Michael Greenberg, MD**

112. Regional and Temporal Variation in Methamphetamine-Related Incidents: Applications of Geographic Information Systems and Spatial Scan Statistics. Sudakin DL, Power LE.

113. Validation of Putative Substances in Poisonings Involved in Fatal Poisonings. Hansen CK, Kashani J, Ruck B, Marcus S.

114. NPDS Data: Situational Awareness of an Emerging Poisoning Epidemic. DesLauriers C, Wahl M.

115. Use of Antivenin for Snake Bites Reported to US Poison Centers (PC). Spiller HA, Bosse GM, Ryan ML.

The participant at the end of this session should be able to:

1. Discuss the use of GIS technologies and spatial scan statistics in evaluating regional and temporal variations in methamphetamine-related incidents.
2. Describe approach to validation of putative substances involved in fatal poisonings.
3. Discuss the use of NPDS data to identify an emerging poisoning epidemic.
4. Describe the reporting of snakebite antivenom administration to US poison centers.



## Monday, September 15, 2008, continued

Jeffrey Brent, MD, PhD  
Clinical Professor of Medicine and Pediatrics, University of Colorado  
Health Sciences Center, Denver, CO

Christine Stork, PharmD, DABAT  
Associate Professor, Emergency Medicine and Medicine, Upstate Medical  
University, Clinical Director, Upstate New York Poison Center, Syracuse,  
NY

David N. Juurlink, BPharm, MD, PhD, FRCPC, FACMT, FAACT, Head,  
Division of Clinical Pharmacology and Toxicology, Sunnybrook Health  
Sciences Centre, Scientist, Institute for Clinical Evaluative Sciences,  
Toronto, Canada

Hugo Kupferschmidt, MD  
Toxicology Consultant, University Hospital, Zuerich, Swiss Toxicological  
Information Centre (STIC), Zuerich, Switzerland

The participant at the end of this session should be able to:

1. Discuss recent evidence-based publications related to medical toxicology.
2. Apply the results of these papers to current toxicology practice.

5:30 pm – 7:00 pm      AAPCC Business/Town Hall Meeting  
Sheraton Hall C  
(Lower Concourse)

6:30 – 8:00 pm              Drexel College of Medicine Former Fellows' Reception  
City Hall (2<sup>nd</sup> Floor)

7:00 pm – 9:00 pm      AAPCC Quiz Bowl  
Grand Ballroom

---

---

## Tuesday, September 16, 2008

7:00 am – 1:00 pm      Speaker Ready Room  
VIP Room (Concourse Level)

**7:00 am – 8:30 am      Continental Breakfast**  
**Grand Foyer**

**7:00 am – 2:00 pm      Registration/Information**  
**Lower Concourse**

**7:00 am – 12:00 pm Exhibits/Poster Session III**  
**Sheraton Hall EF/      Abstracts: #212-305**  
**Grand Ballroom Foyer**

**Tuesday, September 16, 2008, continued**

8:00 am – 10:00 am PEC Steering Committee  
Sheraton Hall A (Lower Concourse)

**8:00 am – 9:00 am**    **AAPCC Symposium: A Brief Guide to Epidemiology for the Poison**  
**Grand Ballroom**    **Center**  
**East**                    **Moderator: Steven Marcus, MD**

William Halperin, MD, MPH, DrPH (**Presentation is not Audio Taped**)  
Professor and Chair, Department of Preventative Medicine, New Jersey  
Medical School, Newark, NJ

The participant at the end of this session should be able to:

1. Describe the basics of conducting an epidemic investigation
2. Discuss the goals and methods of disease surveillance
3. Describe epidemiologic methods in pre-planned studies

**8:00 am – 10:00 am**    **AACT Forensic Symposium: Alcohol Issues**  
**Grand Ballroom**    **Moderators: Cynthia Morris-Kukoski, PharmD, DABAT**  
**Centre**                    **Robert Palmer, PhD, DABAT**

***Medico-Legal Interpretation of Ethanol Results***

John Fisher, PharmD, DABAT, FAACT  
Alabama Poison Center, Tuscaloosa, Alabama

***Medico-Legal Use of Ethanol Testing***

Cynthia Morris-Kukoski, PharmD, DABAT  
Dept of Justice, FBI Laboratory, Quantico, VA

The participant at the end of this session should be able to:

1. Review Ethanol-Induced Behavioral Effects
2. Describe Drug Recognition Examiner and dram shop legislation
3. Discuss the Use, Limitations, Pros & Cons of Breathalyzers
4. Discuss the Use, Limitations, Pros & Cons of Blood Ethanol Analysis

**11:00 am – 1:00 am**    **AACT Occupational/Environmental Symposium II: – Short Course in**  
**Grand Ballroom**    **Risk Assessment**  
**Centre**                    **Moderator: John A. Curtis, MD**

Janet E. Kester, PhD, DABAT  
Newfields, LLC  
NewFields, Wentzville, Missouri

The participant at the end of this session should be able to:

1. Discuss the elements, principles, and objectives of regulatory risk assessment
2. Discuss the proper interpretation and application of risk assessment results
3. Describe risk perception and basic principles of risk communication

**Tuesday, September 16, 2008, continued**

**11:00 am – 12:00 pm Platform Session VI: Adverse Drug Events**

**Grand Ballroom Abstracts: #208-211**

**East Moderator: G. Randall Bond, MD  
Rick Dart, MD, PhD**

208. Clinical Course of Repeated Supratherapeutic Ingestion (RSTI) of Acetaminophen (APAP). Alhelail MA, Hoppe JA, Rhyee SH, Heard KJ, Toxicology Investigator Network.

209. Colchicine Toxicity and Fatality among Hospital Patients. Mullins ME, Cannarozzi AA, Bailey TC, Ranganathan P.

210. Epidemiology of Stevens - Johnson syndrome and Toxic Epidermal Necrolysis in a Regional Burn Center, 1983–2006. O’Connell EJ, Velez LI, Young A, Arnoldo B, Hunt J, Purdue G.

211. Serum Acetaminophen (APAP) Levels, Intravenous N-Acetylcysteine (IV NAC) Infusion Rate and Risk of Anaphylactoid Reactions (AR). Buchanan JA, Phua DH, Mlynarchek SL, Heard K, Toxicology Investigator Network.

The participant at the end of this session should be able to:

1. Describe the clinical course of repeated supratherapeutic acetaminophen ingestion
2. Discuss colchine toxicity and fatality in hospitalized patients
3. Describe the epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis evaluated in a regional burn center
4. Discuss the relationship of serum acetaminophen levels and intravenous N-acetylcysteine infusion rate on the risk of anaphylactoid reactions

**10:00 am – 11:00 am Authors with Posters**

**Sheraton Hall EF Abstracts: #212-305**

**12:00 pm – 1:00 pm Poster Session III Posters Removed**

**Sheraton Hall EF**

**12:15 pm – 1:15 pm AACT Year In Toxicology III: Combat Toxicology: Selected Cases from Operation Iraqi Freedom (Presentation not audio taped)**

**Grand Ballroom from Operation Iraqi Freedom (Presentation not audio taped)**

**East Moderator: Tammi Schaeffer, DO**

MAJ Melissa Givens, MD, MPH  
Assistant Professor, USUHS, Program Director, Emergency Medicine  
Residency, Carl R. Darnall Army Medical Center, Fort Hood, TX

The participant at the end of this session should be able to:

1. Discuss unique aspects of toxicology in a deployed environment.
2. Discuss toxicologic considerations in trauma patients in a combat zone.
3. Discuss toxicologic treatment options and limitations in a deployed environment.

**Tuesday, September 16, 2008, continued**

1:30 pm – 6:00 pm AAPCC Board Meeting (part 2)  
Sheraton Hall A  
(Lower Concourse)

---

***\*\*\*Room Names Subject to Change\*\*\****